Extended Data Table 2 |.

Individual patient treatment summary and outcomes

ID	Number of Infusions	Reason for Discontinuation	Best Clinical Objective Response	Follow up / Progression	PFS (Months)	OS (Months)	Status / Cause of Death
PT0522	10	Adverse event or side effect	PR	No	58	58	Alive
PT0523	7	Progression	PR	20% Increase	7	65	Alive
PT0582	33	Treatment complete	CR	No	49	49	Dead - stroke
PT0535	34	Treatment complete	PR	No	42	42	Dead - sepsis
PT0561	14	Adverse event or side effect	PR	No	13	13	Dead - pulmonary fibrosis
PT0565	3	Adverse event or side effect	PR	No	33	33	Alive
PT0607	1	Refusal unrelated to adverse event1	NA1	No	1	1	Alive
PT0570	20	Other - patient and physician decision	PR	No	54	54	Alive
PT0592	15	Progression	CR	New scalp lesion	11	51	Dead - acute myelogenous leukemia
PT0527	7	Other - patient and physician decision	CR	No	33	33	Dead - cardiac related
PT0710	3	Progression	PD	20% Increase	2	44	Dead - kidney failure
PT0650	17	Adverse event or side effect	uCR	No	60	60	Alive
PT0628	33	Treatment complete	CR	No	60	60	Alive
PT0706	13	Other - patient and physician decision	PR	No	52	52	Alive
PT0723	14	Adverse event or side effect	PR	No	48	48	Alive
PT0718	5	Other - resection	SD	No	51	51	Alive
PT0623	2	Other - sepsis, unrelated to protocol treatment	PR	No	38	38	Dead - brain bleed related to fall
PT0655	19	Other - patient and physician decision	uCR	No	55	55	Alive
PT0681	17	Adverse event or side effect	CR	No	45	45	Alive
PT0772	22	Other - patient and physician decision	PR	No	42	42	Alive
PT0770	20	Progression	PR	20% Increase	14	24	Dead - melanoma brain metastases
PT0777	10	Adverse event or side effect	CR	No	40	40	Alive
PT0796	14	Other - COPD/dyspnea, unrelated to protocol tx	CR	No	21	21	Dead - cardiac related
PT0797	25	Adverse event or side effect	PR	No	34	34	Alive
PT0794	15	Adverse event or side effect	PR	No	36	36	Alive
PT0839	34	Treatment complete	CR	No	34	34	Alive
PT0789	34	Treatment complete	PR	No	31	31	Alive

CR, confirmed complete response; PD, progressive disease; PR, confirmed partial response; SD, stable disease; uCR, unconfirmed complete response.

¹Participant PT0607 withdrew consent after the first cycle of treatment.